AstraZeneca has unveiled plans for a $200 million investment in a new manufacturing facility in China.
The plant, in China Medical City (CMC), Taizhou, Jiangsu province, represents the company's "largest-ever investment in a single manufacturing facility globally". It will produce both intravenous and oral solid medicines and construction of the site is scheduled to be completed at the end of 2013.
Mark Mallon, president of AstraZeneca China, said the company "has been putting down deep and broad roots" in the country for many years, and the new facility "will help us to reach out to more of the estimated 900 million people in urban and rural communities who have had less access to high quality medicines.” AstraZeneca’s turnover in China, where it started operations in 1993, was over $1 billion in 2010 and it employs approximately 5,000 staff.
The company already has a state-of-the-art manufacturing and supply site in Wuxi, also in Jiangsu province, while the AstraZeneca Innovation Centre China (ICC) in Shanghai is described by the firm as "a leading-edge translational science centre targeting, among others, biomarker research into cancer therapies specifically relevant for Chinese and Asian patients". The ICC is one of AstraZeneca’s most advanced scientific research hubs outside the UK, Sweden and USA.